Clinical Trials Directory

Trials / Completed

CompletedNCT04618380

Premium Monovision Versus Other Types of Monovision and Bilateral Trifocal Implantation.

Premium Monovision Versus Bilateral Myopic Monovision, Hybrid Monovision and Bilateral Trifocal Implantation. A Comparative Study.

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
Democritus University of Thrace · Academic / Other
Sex
All
Age
45 Years
Healthy volunteers
Not accepted

Summary

Primary objective of this study was to compare the efficacy of premium monovision with Restor and Panoptix, against other prevalent monovision techniques and against bilateral Panoptix implantation in a sample of patients following lens-extraction surgery.

Detailed description

Four study groups were formed according to the procedure and the intraocular lens technology that was used: a) Monovision Group (MoG), b) Multifocal Lens Group (MfG), c) Hybrid Monovision Group (HmG), and, d) Premium Monovision Group (PmG). Patients who have undergone one of the above categories of presbyopia correction surgery were selected to compare the effectiveness of these techniques by evaluating the uncorrected near, intermediate and distant visual acuity as well as the degree of subjective patient satisfaction, contrast sensitivity, dysphotopsia symptoms and spectacle independence .

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTbUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivityThe following clinical indexes are evaluated: 1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance 2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and 3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS). All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD. Contrast sensitivity are evaluated with the Pelli-Robson test.

Timeline

Start date
2018-01-01
Primary completion
2020-07-31
Completion
2020-11-01
First posted
2020-11-05
Last updated
2020-11-09

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT04618380. Inclusion in this directory is not an endorsement.